None listed
Conditions
Interventions
Intervention1: UP165 (250 mg): 1 capsule approximately 60 ± 10 mins before bed for 4 weeks.
Intervention2: UPI65 (500 mg): 1 capsule approximately 60 ± 10 mins before bed for 4 weeks
Control Intervent
Sponsors
Vedic Lifesciences Pvt. Ltd
Eligibility
Inclusion criteria
Inclusion criteria: Male and female subjects =20 and = 60 years’ old with moderate physical activity level as per International Physical Activity Questionnaire – Short Form (IPAQ - SF) Volunteers with body mass index between 18.5 and 29.9 kg/m2. Fairly bad or very bad subjective sleep quality with a score of 2 or 3 assessed as per PSQI Q9. Willing to maintain current dietary pattern, activity level, and stable body weight for the duration of the study, and refrain from any drastic lifestyle changes. Unable to fall asleep or unable to stay asleep (2 or more waking episodes during sleep at least twice a week but not more than four times) Agrees to maintain current sleep schedule throughout the study Agrees to stay in the current time zone for the duration of the study Subjects ready to give voluntary, written, informed consent to participate in the study. Willing to complete all study procedures including study-related questionnaires and comply with study requirements.
Exclusion criteria
Exclusion criteria: Subjects diagnosed with sleep disorders secondary to another health problem. Consumption of hypnotic drugs ( Subjects with a history of caffeine consumption post 6:00 pm. Individuals taking any other sleep supplements and are unwilling to stop taking those supplements for the duration of the study period Recent history of physical, emotional, social trauma within last three months. Participants who are not medication (which are likely to impact sleep quality or pattern) free for at least 4 weeks apart from contraceptive pills Subjects who consume pain-relieving medications more than once per week. Individuals who have night terrors regularly Individuals who regularly sleepwalk Individuals who work at night shifts. Individuals who have regular bad dreams Use of the following medications during the study period: oral or injectable corticosteroid, sedating antihistamines (e.g. cold, allergy, motion sickness), psychotropic medications or hypnotics, benzodiazepine, narcotics, any illicit drugs Gastro-intestinal, hepatic, respiratory, psychiatric, kidney, or cardiovascular disorder ( Recent ( Students having regular class and assignments Subjects addicted to digital media who exhibit at least five of the following symptoms currently: i) Preoccupation with the digital media use j) Withdrawal symptoms that occur when digital media use is not possible k) Build-up of a tolerance that requires increasing amounts of digital media use to satisfy cravings l) Unsuccessful attempts to stop or limit digital media use m) Replacement of previously pleasurable activities with digital media use n) Unwillingness to stop digital media use despite its negative consequences o) Being deceptive about digital media use p) Using digital media use as a coping mechanism Addiction or history of substance abuse, Consumption of more than 3 glasses of alcohol per day, Pregnant or lactating woman, Lifestyle habits which would modify the wake-sleep rhythm, or which was expected to be modified during the study period (e.g., night work), and finally, Known allergy to the IP.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Sleep statistics by using the Garmin vivosmart 4 Tracker Timepoint: 1. Throughout the study | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. The change in sleep index through the global scores of the Pittsburgh Sleep Quality Index (PSQI). 2. Mood using POMS-A (Profile of Moods States – Abbreviated version). 3. Salivary cortisol immediately after awakeningTimepoint: 1. Day 0, Day 7, Day 14, Day 21 and Day 28 2. Day 0, Day 7, Day 14, Day 21 and Day 28 3. Day 0, Day 7, Day 14, Day 21 and Day 28 | — |
Countries
India
Contacts
Public ContactMr Abhimanyu Kumar
Vedic Lifesciences Pvt. Ltd.
Outcome results
None listed